FDA Adverse Event Malfunction Summary report: N

INRATIO

MDR report key: 1013970 · Received March 14, 2008

Report

Report Number
2954730-2008-00130
Event Type
Malfunction
Date Received
March 14, 2008
Date of Event
February 22, 2008
Report Date
March 14, 2008
Manufacturer
HEMOSENSE SJ
Product Code
JPA
Product Problem
Yes
Report Source
Manufacturer report
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

DISCREPANT RESULTS (ACCURACY) COMPARISON OF INRATIO TEST WITH LAB RESULTS PROVIDED BY END-USER AT TIME COMPLAINT WAS FILED: DATE UNK, INRATIO 1.8, LAB 2.1, MEAN 2.0, CONFIDENCE LIMITS 1.3 - 2.7. DATE: 2008, INRATIO 5.1, LAB 5.7, MEAN 5.4, CONFIDENCE LIMITS CANNOT BE DETERMINED. DATE: SAME DAY, INRATIO 3.7, LAB 5.1, MEAN 4.4, CONFIDENCE LIMITS 2.5 - 6.5. PER INTERNAL PROCEDURE, THE MEAN OF THE INRATIO METER AND COMPARATIVE SYS INR WERE CALCULATED. FOR THE 1ST AND 3RD DATA SET, BOTH INRATIO AND LAB VALUES ARE WITHIN THE CONFIDENCE LIMITS FOR INR TESTING. FOR THE 2ND DATA SET, THE READINGS ARE CONSIDERED ACCURATE BASED ON "AREA OUTSIDE THE ACCEPTANCE REGION" TABLE. THE RESULTS ARE NOT CONSIDERED DISCREPANT WITHIN THE CONTEXT OF THE DOCUMENTED VARIABILITY FOR INR TESTING. THEREFORE, FURTHER TESTING IS NOT REQUIRED AT THIS TIME. INRATIO PRECISION DATA PROVIDED BY END-USER LOT: NI. FIRST TEST INR = 1.1; SECOND TEST INR = 1.3. MEAN = 1.2; SD = 0.14; %CV = 11.8. THE %CV IS LESS THAN 20%. PER INTERNAL PROCEDURE, THE PRECISION PASSES THE CRITERIA FOR PRECISION. THE TEST IS CONSIDERED PRECISE AND FURTHER TESTING IS REQUIRED AT THIS TIME.

Description of Event or Problem · 1

CALLER ALLEGES INACCURACY WITH INRATIO. RESULTS AS FOLLOWS: DATE UNK, INRATIO 1.8, LAB 2.1. DATE: 2008, INRATIO 5.1, LAB 5.7. DATE: SAME DAY, INRATIO 3.7, LAB 5.1. CALLER ALLEGES IMPRECISION WITH INRATIO. RESULTS AS FOLLOWS: FIRST TEST INR = 1.1; SECOND TEST INR = 1.3.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 INRATIO PROTHROMBIN TIME TEST JPA HEMOSENSE SJ KIT, PROFESSIONAL USER, ENGLISH NI

Patients

Seq Age Sex Outcome Treatment
1